Brief: Mirum Pharmaceuticals & GC Pharma Enter Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea

GC Biopharma

27/07/2021 01:04

July 26 (Reuters) - Mirum Pharmaceuticals Inc  MIRM.O :
    * MIRUM PHARMACEUTICALS &GC PHARMA ENTER EXCLUSIVE LICENSING
AGREEMENT TO DEVELOP AND COMMERCIALIZE MARALIXIBAT FOR RARE
LIVER DISEASES IN SOUTH KOREA
    * GC PHARMA TO LEAD DEVELOPMENT AND COMMERCIALIZATION IN
SOUTH
KOREA
    * MIRUM SEEKS TO EXPAND GLOBAL AVAILABILITY OF MARALIXIBAT
IN RARE
LIVER DISEASES
    * GC PHARMA HAS OBTAINED EXCLUSIVE RIGHT TO DEVELOP AND
COMMERCIALIZE MARALIXIBAT WITHIN SOUTH KOREA FOR ALGS, PFIC, AND
BA
    * COMMENCED A GLOBAL PHASE 2B MARALIXIBAT STUDY (EMBARK) FOR
TREATMENT OF BA
    * GC PHARMA  OBTAINED EXCLUSIVE RIGHT TO DEVELOP AND
COMMERCIALIZE
MARALIXIBAT WITHIN SOUTH KOREA FOR ALGS, PFIC, AND BA
    * MIRUM - IN EXCHANGE, CO ENTITLED TO RECEIVE  UPFRONT
PAYMENT OF
$5 MILLION AS WELL PAYMENTS FOR ACHIEVEMENT OF FUTURE REGULATORY
AND COMMERCIAL MILESTONES

Source text for Eikon:  ID:nBwznckfa 
Further company coverage:  MIRM.O 

 ((Reuters.Briefs@thomsonreuters.com;))